

Roberto Castelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9084999/roberto-castelli-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

1,304

citations

19

h-index

34

g-index

77

ext. papers

1,531

ext. citations

3.5

avg, IF

4.51

L-index

#	Paper	IF	Citations
69	Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2720	5.1	0
68	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021 , 11, 167	7	1
67	Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments. <i>Anti-Cancer Drugs</i> , 2021 , 32, 323-329	2.4	
66	Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021 , 10, 3839-3847	4.7	2
65	Massive Right Atrial Thrombosis: Are You Brave Enough to Start Anticoagulation? A Case Report. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 688351	5.4	2
64	Eltrombopag reduces bleeding complications and the need of platelet transfusions in cirrhotic thrombocytopenic patients subjected to invasive procedures. <i>Blood Coagulation and Fibrinolysis</i> , 2021 , 32, 163-166	1	
63	Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. <i>Clinical and Experimental Immunology</i> , 2020 , 201, 258-265	6.2	7
62	Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e461-e467	2	1
61	Risk Of Thrombosis In Elderly Immune Primary Trombocytopenic Patients Treated with Thrombopoietin Receptors Agonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 903-907	5.1	4
60	HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020 , 20, 175-180	1.1	2
59	HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020 , 20, 175-180	1.1	2
58	Ibrutinib related bleeding complications in elderly patients with B cell malignancies. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 694-696	5.1	3
57	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1336-1351	2.2	45
56	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>Blood Advances</i> , 2019 , 3, 1197-1210	7.8	39
55	Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 155-156	5.1	2
54	The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes. <i>Medical Oncology</i> , 2018 , 35, 33	3.7	6
53	Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents. <i>Medical Oncology</i> , 2018 , 35, 76	3.7	6

52	High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 106-113	5.1	11
51	Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization. <i>Medical Oncology</i> , 2018 , 35, 118	3.7	12
50	Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant. <i>Annals of Hematology</i> , 2018 , 97, 2523-2525	3	
49	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 22-32	5.4	6
48	Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study. <i>Annals of Hematology</i> , 2017 , 96, 779-786	3	6
47	Personalized treatment strategies for elderly patients with myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2017 , 10, 1077-1086	2.8	5
46	First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas. <i>Medical Oncology</i> , 2017 , 35, 15	3.7	7
45	The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 207-14	5.9	27
44	High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiency. <i>British Journal of Haematology</i> , 2016 , 172, 902-8	4.5	29
43	Laboratory and clinical risk assessment to treat myelodysplastic syndromes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 1411-26	5.9	7
42	Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016030	3.2	4
41	High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. <i>Digestive and Liver Disease</i> , 2016 , 48, 1394-1397	3.3	18
40	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. <i>Leukemia Research</i> , 2015 , 39, 525-9	2.7	10
39	Neutrophilic progression in a case of polycythemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. <i>Pathology Research and Practice</i> , 2015 , 211, 341-3	3.4	4
38	Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. <i>Anti-Cancer Drugs</i> , 2015 , 26, 1078-82	2.4	8
37	Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2015 , 126, 5378-5378	2.2	
36	High Prevalence of Marginal ZONE Lymphoma Among Patients with Acquired C1- Inhibitor Deficiency. <i>Blood</i> , 2015 , 126, 1444-1444	2.2	
35	Thrombosis and hemostatic abnormalities in hematological malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 441-50	2	35

34	Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. <i>Annals of Hematology</i> , 2014 , 93, 1523-9	3	21
33	Pulmonary embolism in elderly patients: prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality. <i>Thrombosis Research</i> , 2014 , 134, 326-30	8.2	13
32	Choosing treatment options for patients with relapsed/refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 199-215	3.5	5
31	Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 1-7	2	18
30	Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 323-32	7	43
29	Rheumatoid factors: clinical applications. <i>Disease Markers</i> , 2013 , 35, 727-34	3.2	148
28	Current and emerging treatment options for patients with relapsed myeloma. <i>Clinical Medicine Insights: Oncology</i> , 2013 , 7, 209-19	1.8	20
27	Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinic. <i>Immunopharmacology and Immunotoxicology</i> , 2013 , 35, 181-90	3.2	5
26	Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding. <i>Internal and Emergency Medicine</i> , 2012 , 7, 237-42	3.7	17
25	Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patients. <i>Immunopharmacology and Immunotoxicology</i> , 2012 , 34, 717-20	3.2	5
24	Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. <i>Immunopharmacology and Immunotoxicology</i> , 2012 , 34, 740-53	3.2	14
23	Interaction of C1 inhibitor with thrombin on the endothelial surface. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 571-5	1	19
22	Lymphoproliferative Disorder and Acquired C1-INH Deficiency. A Case Series of 48 Patients. <i>Blood</i> , 2011 , 118, 1596-1596	2.2	
21	Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA. <i>European Journal of Internal Medicine</i> , 2010 , 21, 25-9	3.9	2
20	Thromboembolic complications in malignant haematological disorders. <i>Current Vascular Pharmacology</i> , 2010 , 8, 482-94	3.3	28
19	The impact of an aging population on the diagnosis of pulmonary embolism: comparison of young and elderly patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009 , 15, 65-72	3.3	15
18	Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. <i>International Journal of Laboratory Hematology</i> , 2008 , 30, 425-31	2.5	22
17	Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008 , 8, 156-9	13.6	78

16	Lymphoproliferative disease and acquired C1 inhibitor deficiency. <i>Haematologica</i> , 2007 , 92, 716-8	6.6	56
15	Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2007 , 7, 153-62	1.1	18
14	Aggressive natural killer cell leukaemia with a complex karyotype: a case report. <i>Annals of Hematology</i> , 2006 , 85, 66-8	3	4
13	Unusual severe development of common B lymphoblastic leukemia in Gaucher disease type I. <i>American Journal of Hematology</i> , 2006 , 81, 383-4	7.1	3
12	The value of four-detector row spiral computed tomography for the diagnosis of pulmonary embolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 831-7	5.3	6
11	Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. <i>Immunology and Allergy Clinics of North America</i> , 2006 , 26, 669-90	3	83
10	New antithrombotic agents. <i>Panminerva Medica</i> , 2006 , 48, 247-56	2	2
9	The heparins and cancer: review of clinical trials and biological properties. <i>Vascular Medicine</i> , 2004 , 9, 205-13	3.3	64
8	Unreliable estimation of HbA due to the presence of Camperdown haemoglobin [beta 104 (G6) Arg --> Ser]. <i>Diabetic Medicine</i> , 2004 , 21, 377-9	3.5	3
7	Intrathoracic masses due to extramedullary hematopoiesis. <i>American Journal of the Medical Sciences</i> , 2004 , 328, 299-303	2.2	23
6	Syncope in patients with pulmonary embolism: comparison between patients with syncope as the presenting symptom of pulmonary embolism and patients with pulmonary embolism without syncope. <i>Vascular Medicine</i> , 2003 , 8, 257-61	3.3	59
5	Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor. <i>Transfusion</i> , 1998 , 38, 307-11	2.9	16
4	Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. <i>Journal of Allergy and Clinical Immunology</i> , 1997 , 99, 194-6	11.5	132
3	Cardiopulmonary By-pass in a Patient with Acquired C1 Inhibitor Deficiency. <i>International Journal of Artificial Organs</i> , 1997 , 20, 175-177	1.9	6
2	Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency. <i>International Journal of Artificial Organs</i> , 1997 , 20, 175-7	1.9	
1	Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. <i>Transfusion</i> , 1995 , 35, 209-12	2.9	36